Third Quarter 2025 Results / Quarterly Reports
Bayer Q3 2025 Media Update
Bayer confirms 2025 Group outlook, progresses on strategic priorities
- Group sales at 9.660 billion euros (Fx & portfolio adj. plus 0.9 percent)
- EBITDA before special items increases 20.8 percent to 1.511 billion euros
- Crop Science posts higher sales (Fx & portfolio adj.) and strong earnings growth
- Pharmaceuticals sales at prior-year level (Fx & portfolio adj.), earnings down
- Consumer Health reports moderate sales growth (Fx & portfolio adj.) and stable earnings
- Core earnings per share rise 137.5 percent to 0.57 euros
- Net income at minus 963 million euros, impacted by special charges for litigations
- Free cash flow declines to 596 million euros
- Net financial debt reduced slightly to 32.708 billion euros
- Adjustment to 2025 sales expectation at Consumer Health, Group guidance confirmed
Strategy and Financial Update
Video Webcast
Recording of the Media Update